Background Pituitary carcinomas are rare but aggressive and require maximally coordinated
multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ) …

This review focuses on discussing the main changes on the upcoming fourth edition of the
WHO Classification of Tumors of the Pituitary Gland emphasizing histopathological and …

Object The 2004 WHO classification of pituitary adenomas now includes an “atypical”
variant, defined as follows: MIB-1 proliferative index greater than 3%, excessive p53 …

Aggressive pituitary adenomas (PAs) are clinically challenging for endocrinologists and
neurosurgeons due to their locally invasive nature and resistance to standard treatment …

Adenohypophyseal tumors, which were recently renamed pituitary neuroendocrine tumors
(PitNET), are mostly benign, but may present various behaviors: invasive,“aggressive” and …

Pituitary tumors (PTs) are a heterogeneous group of lesions of the central nervous system
that are usually benign. Most of them occur sporadically, but 5% can do so within family …

Context: Although pituitary adenomas are common, pituitary carcinoma is a very rare
condition. Objective: We report on a 48-yr-old male presenting with pituitary carcinoma with …

Objective The prognosis of either pituitary carcinoma or aggressive pituitary adenoma
resistant to standard therapies is poor. We assessed the efficacy of treatment with …

Pituitary adenomas (PAs) are benign lesions; nonetheless, some PAs exhibit aggressive
behaviors, which lead to recurrence. The impact of pituitary dysfunction, invasion-related …

Pituitary carcinomas are rare, accounting for about 0· 2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …